WO2005082928A3 - Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite - Google Patents

Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Download PDF

Info

Publication number
WO2005082928A3
WO2005082928A3 PCT/GB2005/000710 GB2005000710W WO2005082928A3 WO 2005082928 A3 WO2005082928 A3 WO 2005082928A3 GB 2005000710 W GB2005000710 W GB 2005000710W WO 2005082928 A3 WO2005082928 A3 WO 2005082928A3
Authority
WO
WIPO (PCT)
Prior art keywords
gip
diabetes
treatment
peptide analogues
obesity
Prior art date
Application number
PCT/GB2005/000710
Other languages
English (en)
Other versions
WO2005082928A2 (fr
Inventor
Victor A Gault
Finbarr Paul Mary O'harte
Peter Raymond Flatt
Nigel Irwin
Patrick Harriot
Original Assignee
Univ Ulster
Victor A Gault
Finbarr Paul Mary O'harte
Peter Raymond Flatt
Nigel Irwin
Patrick Harriot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ulster, Victor A Gault, Finbarr Paul Mary O'harte, Peter Raymond Flatt, Nigel Irwin, Patrick Harriot filed Critical Univ Ulster
Priority to EP05717793A priority Critical patent/EP1730188A2/fr
Priority to JP2007500292A priority patent/JP2008500280A/ja
Priority to AU2005217198A priority patent/AU2005217198A1/en
Priority to CA2557151A priority patent/CA2557151C/fr
Priority to US11/090,787 priority patent/US20050272652A1/en
Publication of WO2005082928A2 publication Critical patent/WO2005082928A2/fr
Publication of WO2005082928A3 publication Critical patent/WO2005082928A3/fr
Priority to US11/713,892 priority patent/US7875587B2/en
Priority to US11/825,293 priority patent/US20080009603A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des analogues peptidiques qui sont des antagonistes du peptide inhibiteur gastrique (GIP). Les peptides, sur la base du GIP 1-42, comportent des substitutions et/ou des modifications qui améliorent la résistance à la dégradation par la dipeptidylpeptidase IV (DPP IV). L'invention concerne également un procédé de modification de la terminaison N de GIP ainsi que l'utilisation d'analogues peptidiques destinés au traitement de diabètes.
PCT/GB2005/000710 1999-03-29 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite WO2005082928A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP05717793A EP1730188A2 (fr) 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite
JP2007500292A JP2008500280A (ja) 2004-02-25 2005-02-25 糖尿病、インスリン抵抗性、及び肥満症の治療のためのｇｉｐペプチド・アナログ
AU2005217198A AU2005217198A1 (en) 2004-02-25 2005-02-25 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CA2557151A CA2557151C (fr) 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite
US11/090,787 US20050272652A1 (en) 1999-03-29 2005-03-25 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US11/713,892 US7875587B2 (en) 1999-03-29 2007-03-05 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US11/825,293 US20080009603A1 (en) 1999-03-29 2007-07-03 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0404124.0A GB0404124D0 (en) 2004-02-25 2004-02-25 Antagonists of GIP
GB0404124.0 2004-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/090,787 Continuation-In-Part US20050272652A1 (en) 1999-03-29 2005-03-25 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity

Publications (2)

Publication Number Publication Date
WO2005082928A2 WO2005082928A2 (fr) 2005-09-09
WO2005082928A3 true WO2005082928A3 (fr) 2005-12-01

Family

ID=32050802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/000710 WO2005082928A2 (fr) 1999-03-29 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite

Country Status (6)

Country Link
EP (1) EP1730188A2 (fr)
JP (1) JP2008500280A (fr)
AU (1) AU2005217198A1 (fr)
CA (1) CA2557151C (fr)
GB (1) GB0404124D0 (fr)
WO (1) WO2005082928A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900593B2 (en) 2007-02-15 2014-12-02 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119749A (zh) 2004-10-25 2008-02-06 赛托斯生物技术公司 肠抑胃肽(gip)抗原阵列及其用途
WO2007028633A2 (fr) * 2005-09-08 2007-03-15 Uutech Limited Traitement de l'obesite associee aux diabetes
WO2007028632A2 (fr) * 2005-09-08 2007-03-15 Uutech Limited Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
GB0717388D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
WO2009058662A2 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon
EP2224945B1 (fr) * 2007-11-23 2012-05-16 Michael Rothkopf Procédés d'amplification de la résolution d'un diabète
KR20110040760A (ko) 2008-06-17 2011-04-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CN104447980A (zh) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
GB0814068D0 (en) * 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
EP2323678B1 (fr) * 2008-08-07 2016-03-23 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
MX2011001031A (es) * 2008-08-07 2011-04-26 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa.
EP2320923B1 (fr) * 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Analogues tronqués de polypeptide insulinotrope glucose-dépendant
EP2376097A4 (fr) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Promédicaments peptidiques de la superfamille du glucagon à base d'amide
JP5576694B2 (ja) * 2009-04-10 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2797095A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
BR112012028707A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
US9023986B2 (en) * 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
JP2020521784A (ja) * 2017-05-31 2020-07-27 ユニバーシティ オブ コペンハーゲン 長時間作用性ｇｉｐペプチド類似体
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
ES2961384T3 (es) * 2018-05-04 2024-03-11 Novo Nordisk As Derivados de GIP y usos de los mismos
CN113827706B (zh) * 2021-09-27 2023-12-26 南通大学 Gip及其衍生肽作为制备皮肤创伤治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058360A2 (fr) * 1999-03-29 2000-10-05 Uutech Limited Peptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058360A2 (fr) * 1999-03-29 2000-10-05 Uutech Limited Peptide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IRWIN NIGEL ET AL: "A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. SEP 2005, vol. 314, no. 3, September 2005 (2005-09-01), pages 1187 - 1194, XP008052103, ISSN: 0022-3565 *
See also references of EP1730188A2 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8900593B2 (en) 2007-02-15 2014-12-02 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9447162B2 (en) 2007-02-15 2016-09-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Also Published As

Publication number Publication date
CA2557151A1 (fr) 2005-09-09
WO2005082928A2 (fr) 2005-09-09
JP2008500280A (ja) 2008-01-10
CA2557151C (fr) 2015-02-17
AU2005217198A1 (en) 2005-09-09
GB0404124D0 (en) 2004-03-31
EP1730188A2 (fr) 2006-12-13

Similar Documents

Publication Publication Date Title
WO2005082928A3 (fr) Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite
WO2000058360A3 (fr) Peptide
BE2021C505I2 (fr)
WO2006024275A3 (fr) Invention concernant le glp-1 et l'exendine
TW200616657A (en) Therapeutic peptides and method
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
WO2003082898A3 (fr) Nouveaux analogues du polypeptide insulinotropiquedependant du glucose (gip)
WO2006042152A3 (fr) Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs
WO2006053043A3 (fr) Methodes de traitement du diabete sucre
WO2006127757A3 (fr) Fusion interferon-igg
WO2007028633A3 (fr) Traitement de l'obesite associee aux diabetes
TW200507870A (en) GLP-1 analog fusion proteins
EP1756074A4 (fr) Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes
WO2007019865A3 (fr) Traitement au moyen de peptides de liaison cd4 et par rayonnements
WO2004096854A3 (fr) Analogues de l'insuline ayant une action prolongee
WO2009014650A3 (fr) Exotoxines recombinantes de vibrio cholerae
MX2022001137A (es) Compuestos agonistas de gipr.
WO2010054326A3 (fr) Fragments c-terminaux du peptide 1 de type glucagon (glp-1)
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2004050115A3 (fr) Polytherapie mettant en oeuvre des exendines et des thiazolidinediones
WO2006042745A3 (fr) Analogues de peptides modifies chimiquement
WO2008045015A8 (fr) Purification d'imino- et amino-sucre
EP1753446A4 (fr) Alpha-1- acide glycoproteine pour le traitement des diabetes
WO2008085982A3 (fr) Procédés et compositions de traitement de troubles hypoglycémiques
WO2007015069A3 (fr) Compositions et methodes de traitement du diabete

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11090787

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005217198

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2557151

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007500292

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2005217198

Country of ref document: AU

Date of ref document: 20050225

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005217198

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005717793

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005717793

Country of ref document: EP